Obesity correlation with metastases development and response to first-line metastatic chemotherapy in breast cancer

Clinical Medicine Insights: Oncology

Volumn 9, Issue , 2015, Pages 105-112

  Osman, Mohammed A ^a   Hennessy, Bryan T ^a  

^a OUR LADY OF LOURDES HOSPITAL   (Ireland)

Author keywords

Obesity; ORR; OS; Paclitaxel; PFS; Visceral

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER GRADING; CLINICAL TRIAL (TOPIC); CORRELATIONAL STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; IRELAND; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OBESITY; OVERALL SURVIVAL; PREMENOPAUSE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VISCERAL METASTASIS;

EID: 84948990910     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S32812     Document Type: Article

References (28)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-41.
2. Peytremann-Bridevaux I, Faeh D, Santos-Eggimann B. Prevalence of overweight and obesity in rural and urban settings of 10 European countries. Prev Med. 2007;44:442-6.
3. Martorell R, Kettel K, Hughes MH. Obesity in women from developing countries, 2000. Int J Obesity. 2000;24:959-67.
4. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197-209.
5. Ballard-Barbash R, Berrigan D, Potischman N, Dowling E. Obesity and cancer epidemiology. In: Berger NA, ed. Cancer and Energy Balance, Epidemiology and Overview. New York: Springer-Verlag New York, LLC; 2010:45-63.
6. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst. 2009;101(9):630-43.
7. Ewertz M, Jensen M-B, Gunnarsdóttir KÁ, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29:25-31.
8. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28:3411-5.
9. Pan H, Gray RG; Early Breast Cancer Trialists' Collaborative Group. Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. ASCO annual meting 2014, abstract number 503. J Clin Oncol. 2014;32:35. [suppl; abstr 503].
10. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301-16.
11. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556-65.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
13. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. N Engl J Med. 2003;348(17):1625-38.
14. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Br Med J. 2007;335(7630):1134-9.
15. Poikonen P, Blomqvist C, Joensuu H. Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. Acta Oncol. 2001;40(1):67-71.
16. Greenman CG, Jagielski CH, Griggs JJ. Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer. 2008;112(10):2159-65.
17. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128-43.
18. Cui Y, Whiteman MK, Flaws JA, Langenberg P, Tkaczuk KH, Bush TL. Body mass and stage of breast cancer at diagnosis. Int J Cancer. 2002;98:279-83.
19. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-73.
20. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42-51.
21. Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2000;2:170-5.
22. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev. 2009;18:2569-78.
23. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131-5.
24. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219-46.
25. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004;10:4325-31.
26. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004;89:1102-7.
27. Litton JK, Gonzalez-Angulo AM, Warneke CL, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008;26(25):4072-7.
28. Widschwendter P, Friedl T, Schwentner L, et al. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res. 2015;17:129.